Lexicon Pharmaceuticals(NASDAQ) LXRX

Lexicon Pharmaceuticals, Inc. makes medicines for heart failure. It also develops daily pills to help treat chronic pain. These treatments help patients live healthier and more comfortable lives.

Helping Hearts and Healing Nerves

• INPEFA: Approved oral drug reducing cardiovascular risks in adults with heart failure.
• ZYNQUISTA: Investigative medicine for type 1 diabetes currently undergoing regulatory review.
• Pilavapadin: Small molecule drug candidate in Phase 2 clinical trials for neuropathic pain.
• LX9851: Preclinical drug candidate for obesity licensed to a global pharmaceutical partner.

Partnerships and Progress

• Signed a global licensing deal with Novo Nordisk in March 2025 for LX9851.
• Entered an agreement with Viatris in October 2024 for international drug sales.
• Repaid all outstanding debt to Oxford in May 2026.
• Secured a new $100 million loan from Hercules Capital in May 2026.
• Completed patient enrollment for the SONATA-HCM Phase 3 clinical trial.

The Science of Gene Research

Lexicon uses gene-knockout technology to study how thousands of genes function in living animals. This internal discovery engine has identified more than 100 potential drug targets for future medical research.

Key Performance Data

• Revenue was $0.7 million for the three months ended June 30, 2026.
• Net loss was $31.8 million for the three months ended June 30, 2026.
• Research and development expenses rose 11% year over year in the second quarter of 2026.
• Selling, general and administrative expenses fell 10% for the six-month period ended June 30, 2026.
• Cash and short-term investments totaled $190.6 million at the end of June 2026.

Bottom Line

Lexicon has transitioned from a pure research firm to a commercial stage company with an approved heart failure drug. Its future depends on clinical trial outcomes and successful partnerships for its pain and obesity candidates.